CD40.Pan.Cov (LinKinVax)

N/A

Report date: 2026/05/06 20:02:28

Base Information

Drug NameCD40.Pan.Cov (LinKinVax)
Drug Alias NameCOVID19-CD40-PAN-CoV vaccineCOVID19.CD40.PAN.CoV vaccinePan-coronavirus vaccine
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Inactivated vaccine > Subunit vaccine
Mechanisms of ActionImmunostimulantsSARS-CoV-2 Spike glycoprotein receptor binding domain antagonistsTumor necrosis factor receptor superfamily member 5 modulators
TargetsTumor necrosis factor receptor superfamily member 5SARS-CoV-2 Spike glycoprotein receptor binding domain
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesLinKinVax
China Registration ClassN/A

Develop Information

Active CompaniesInstitut National De La Santé Et De La Recherche Médicale, France U979LinKinVax
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A